EN DE
STOCK COMPARISON

BioGaia AB (publ) vs Merck & Company: Fair Value & Quality

Both stocks run through our valuation models. Here is how BioGaia AB (publ) (BIOG-B) and Merck & Company (MRK) compare, as of Sep 5, 2026.

As of Sep 5, 2026, Fair Value Calculator sees Merck & Company as the less overvalued of the two: BioGaia AB (publ) trades at SEK 113 versus a fair value of SEK 70.27 (-38%), while Merck & Company trades at $150 versus $125 (-17%).
BioGaia AB (publ)
BIOG-B.ST · SEK · Health Care
-38%
upside to fair value
overvalued
PriceSEK 113
Fair ValueSEK 70.27
Quality87/100
Merck & Company
MRK · USD · Health Care
-17%
upside to fair value
overvalued
Price$150
Fair Value$125
Quality70/100
Get comparisons like this free by email every month: the most undervalued quality stocks.

Head-to-head numbers

Green value = the better side for that row (for valuation multiples: lower = cheaper).

BioGaia AB (publ)Merck & Company
Valuation
36.4×P/E (TTM)43.5×
8.17×P/S (TTM)4.64×
9.61×P/B5.80×
26.7×EV/EBITDA11.4×
—PEG6.10×
−38.0%Fair value upside−16.6%
3.5%Dividend yield2.2%
SEK 4.00Dividend per share$3.28
Profitability
26%Operating margin39%
0.88×EBIT margin trend (5Y)2.70×
21%Return on equity19%
14%Return on assets13%
Growth
2%Revenue growth (YoY)5%
11.7%Avg. growth/yr (3Y)3.1%
15.5%Avg. growth/yr (5Y)9.4%
+14.6%Value creation/yr+16.0%
Balance & size
48.8×Interest coverage (EBIT/interest)17.3×
—Debt / equity0.89×
$1BMarket cap$305B
healthyGrowth qualityhealthy

Merck & Company leads: 6 to 7 metric wins.

Dash = not meaningfully computable, for example with negative equity.

Quality in detail

The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.

BioGaia AB (publ)of which business quality 83 · market factors 57 Merck & Companyof which business quality 68 · market factors 89
ProfitabilityMargins and returns on capital today
89
74
Quality GrowthAre margins and returns improving?
58
36
CashflowEarnings quality: real cash, not paper profit
70
65
Fin. StrengthBalance sheet, leverage, solvency risk
100
68
InvestmentDisciplined investing over empire-building
100
71
Low VolatilityCalm price path (market factor)
86
83
MomentumPrice trend over the last 3–12 months (market factor)
44
86
52W MomentumDistance to the 52-week high (market factor)
48
100
Net IssuanceBuybacks instead of dilution
81
91

What the models say

How far the median fair value (base case) per model family sits from the current price, in percent. The amount in the currency of the trading venue is shown underneath.

above the price, more than 15% above close to the price, 85% to 115% of the price below the price, more than 15% below

Model familyBioGaia AB (publ)Price SEK 113Merck & CompanyPrice $150
DCF Models-21%below the priceSEK 89.36-22%below the price$117
Earnings-Based-57%below the priceSEK 48.45-58%below the price$62.77
Dividend Discountn/a-60%below the price$60.35
Multiples-44%below the priceSEK 63.85-19%below the price$122
Asset-Based-92%below the priceSEK 8.94-91%below the price$14.27
Growth DCF-31%below the priceSEK 78.25-51%below the price$74.00
Economic Profit-64%below the priceSEK 41.15-44%below the price$83.85
Growth Earnings-36%below the priceSEK 73.14-8%close to the price$138
Minimum-92%below the priceSEK 8.94-91%below the price$14.27
Maximum-21%below the priceSEK 89.36-8%close to the price$138
Median-44%below the priceSEK 63.85-47%below the price$78.93
Geometric mean-58%below the priceSEK 47.94-53%below the price$71.25

Minimum, maximum, median and geometric mean refer to the family values in this table. Geometric because deviations are ratios: half the price and twice the price average to 100%, not 125%.

BioGaia AB (publ): 23 of 24 models see the stock below the current price.

Merck & Company: 24 of 26 models see the stock below the current price.

Scenario ranges

From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.

BioGaia AB (publ)
Bear SEK 54.06Fair Value SEK 70.27Bull SEK 95.08
SEK 113 = current price (white tick)
Merck & Company
Bear $70.92Fair Value $125Bull $188
$150 = current price (white tick)

Compare two other stocks

Tap a field and type again, ticker or company name.

Free, no sign-up

Ranked within their sector

Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.

BioGaia AB (publ) · Health Care

Quality score87 · Top 25%
Fair value upside-38% · below median

Merck & Company · Health Care

Quality score70 · Top 25%
Fair value upside-17% · above median

Bottom line

As of Sep 5, 2026, Fair Value Calculator sees Merck & Company as the less overvalued of the two: BioGaia AB (publ) trades at SEK 113 versus a fair value of SEK 70.27 (-38%), while Merck & Company trades at $150 versus $125 (-17%).

BioGaia AB (publ) has the higher quality score (87/100).

See the full analysis →
BioGaia AB (publ) · Merck & Company

More comparisons

Popular match-ups from the same sectors, all with fair value and quality score.

Related to BioGaia AB (publ)

Eli Lilly and vs UnitedHealth GroupJohnson & Johnson vs UnitedHealth GroupAbbVie vs UnitedHealth GroupMerck & Company vs UnitedHealth Group

Related to Merck & Company

AstraZeneca vs UnitedHealth GroupThermo Fisher Scientific vs UnitedHealth GroupAmgen vs UnitedHealth GroupAbbott Laboratories vs UnitedHealth Group
Free · Top-25 report

See the undervalued quality stocks every month

Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.

A model-based valuation snapshot from 26 models. Values change with price and fundamentals; the date shown above applies.